Anti-(notch Ligand Dll4/vascular Endothelial Growth Factor) (synthetic Human Pr-1283233 Heavy Chain)
Anti-(notch Ligand Dll4/vascular Endothelial Growth Factor) (synthetic Human Pr-1283233 Heavy Chain) Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-(notch Ligand Dll4/vascular Endothelial Growth Factor) (synthetic Human Pr-1283233 Heavy Chain) is under investigation in clinical trial NCT03368859 (A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab).
| Trade Name | Anti-(notch Ligand Dll4/vascular Endothelial Growth Factor) (synthetic Human Pr-1283233 Heavy Chain) |
| Generic | Dilpacimab |
| Dilpacimab Other Names | Dilpacimab, Immunoglobulin, anti-(notch ligand dll4/vascular endothelial growth factor) (synthetic human pr-1283233 heavy chain), disulfide with synthetic human pr-1283233 light chain, dimer |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Anti-(notch Ligand Dll4/vascular Endothelial Growth Factor) (synthetic Human Pr-1283233 Heavy Chain)
